BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Celgene (CELG)'s Pomalidomide Helps in Myeloma After Others Fail


12/11/2012 8:17:52 AM

Celgene Corp. (CELG), the world’s fourth- largest biotechnology company, said its experimental medicine for multiple myeloma helped fight the cancer after other therapies failed. Patients taking Celgene’s pomalidomide plus a low dose of the steroid dexamethasone lived a median 3.6 months without their disease worsening, compared with 1.8 months for patients taking a high dose of the steroid alone, according to data presented at the American Society of Hematology meeting in Atlanta today. The U.S. Food and Drug Administration is set to make a decision on approval of pomalidomide by Feb. 10. European regulators are expected to decide in the second half of 2013, Summit, New Jersey-based Celgene said in a statement today. Pomalidomide, given orally, may draw more than $1 billion in annual revenue by 2017, according to the average of four analysts’ estimates compiled by Bloomberg. The 455-person study, from the third and final phase of clinical trials generally required for approval, consisted of participants who had already taken Celgene’s Revlimid or Takeda Pharmaceutical Co. (4502)’s Velcade. The prognosis in multiple myeloma patients for whom those therapies have stopped working is poor, with a median survival time of nine months, research has shown. Multiple myeloma is a cancer of the white blood cells that will be diagnosed in an estimated 21,700 Americans this year, according to the National Cancer Institute. About 10,710 people will die from the disease in 2012, the institute estimates.

Read at Bloomberg
Read at MSN
Read at RTT News

Bloomberg
MSN
RTT News
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->